Serum levels of IL-10, IL-6, IL-1ra, and sIL-2R in patients with psoriatic arthritis

Rheumatology International

Volumn 19, Issue 3, 2000, Pages 101-105

  Elkayam, O ^a   Yaron, I ^a   Shirazi, I ^a   Yaron, M ^a   Caspi, D ^a  

^a TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

Author keywords

IL 10; IL 1ra; IL 6; Psoriatic arthritis; sIL 2R

Indexed keywords

CYTOKINE; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 6;

ADULT; ARTICLE; BACKACHE; BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION FUNCTION; DISEASE ACTIVITY; DISEASE SEVERITY; ENZYME IMMUNOASSAY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HAND GRIP; HUMAN; JOINT STIFFNESS; MALE; PRIORITY JOURNAL; PSORIATIC ARTHRITIS;

EID: 0034077304     PISSN: 01728172     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002960050111     Document Type: Article

References (21)

1. 1. Gladman D, Farewell VT, Nadeau C (1995) Clinical indicators of progression in psoriatic arthritis: multivariate relative risk model. J Rheumatol 22: 675-679
2. 2. Gottlieb AB, Chang CK, Posnett DN, Finely B, Tam JP (1988) Detection of transforming growth factor (alpha) in normal, malignant and hyperproliferative human keratinocytes. J Exp Med 167: 670-675
3. 3. Grossman RM, Krueger J, Yourish D, Granelli-Peperno A, Murphy DM, May LT, Kupper TS, Sehgal PP, Gotlieb AB (1989) Interleukin 6 is expressed in high levels in psoriatic arthritis and stimulates proliferation of cultured human keratinocytes. Proc Natl Acad Sci USA 86: 6367-6371
4. 4. Prens EP, Benne K, Van Damme J, Bakkus M, Brakel K, Benner R, Van Joost T (1990) Interleukin-1 and interleukin 6 in psoriasis. J Invest Dermatol 95[Suppl]: 121S-124S
5. 5. Holt I, Cooper G, Denton J, Meger A, Hopkins JJ (1992) Cytokine inter-relationships and their association with disease activity in arthritis. Br J Rheumatol 31: 725-733
6. 6. Spadaro A, Taccari E, Riccieri V, Sensi F, Silli Scavelli A, Zoppini A (1996) Interleukin 6 and soluble interleukin-receptor in psoriatic arthritis: correlations with clinical and laboratory parameters. Clin Exp Rheumatol 4: 413-416
7. 7. Salvarini C, Macchioni P, Boiardi L, Rossi F, Casadei Maldini M, Mancini R, Beltrandi E, Lodi L, Bsighini G, Portioli I (1992) Low dose cyclosporine A in psoriatic arthritis - relation between soluble interleukin 2 receptors and response to therapy. J Rheumatol 19: 74-79
8. 8. Kapp A, Piskorski A, Schopt E (1988) Elevated level of interleukin 2 receptor in sera of patients with atopic dermatitis and psoriasis. Br J Dermatol 119: 707-710
9. 9. Gladman DD, Shickett R, Russel ML, Thorne JC, Schachter RK (1987) Psoriatic arthritis - an analysis of 220 patients. QJM 62: 127-141
10. 10. Carson DA, Lotz M (1989) Synovium as a source of interleukin 6 in vitro: contribution to local and systemic manifestations of arthritis. J Clin Invest 84: 585-592
11. 11. Katsikis PD, Chu CQ, Brennan FM et al. (1994) Immunoregulatory role of interleukin 10 in rheumatoid arthritis. J Exp Med 179: 1517-27
12. 12. Mussi A, Bonifati C, Carducci M, Viola M, Tomaselli I, Sacerdoti G, Fazio M, Ameglio F (1994) Interleukin 10 levels are decreased in psoriatic lesional skin as compared to the psoriatic lesion-free and normal skin suction blister fluids. J Biol Regul Homeost Agents 8: 117-120
13. 13. Asadullah K, Sterry W, Stephanek K, Jasulaitis D, Leupold M, Audring H, Volk HD, Docke WD (1998) Interleukin 10 is a key cytokine in psoriasis. Proof of principle by IL-10 therapy -a new therapeutic approach. J Clin Invest 101: 783-794
14. 14. Seitz M, Loetscher P, Dewald B, Towbin H, Rordor FC, Gallati H, Gerber NJ (1996) Interleukin 1 (IL-1) receptor antagonist, soluble tumor necrosis factor receptors, IL-1 Beta and IL-8 markers of remission in rheumatoid arthritis during treatment with methotrexate. J Rheumatol 23: 1512-1516
15. 15. Gabay C, Gay-Crosier F, Roux-Lombard et al. (1994) Elevated serum levels of interleukin-1 receptor antagonist in polymyositis/dermatomyositis. Arthritis Rheum 37: 1744
16. 16. Suzuki H, Takemura H, Kashiwaga H (1995) Interleukin-1 receptor antagonist in patients with active systemic lupus erythematosus in patients with active systemic lupus erythematosus: enhanced production by monocytes and correlation with disease activity. Arthritis Rheum 38: 1055
17. 17. Nicoletti F, Patti F, Di Marco R, Zaccone P, Nicoletti A, Menori P, Reggio A (1996) Circulating serum levels of IL-1ra in patients with relapsing remitting multiple sclerosis are normal during remission phases but significantly increased either during exacerbations or in response to IFN-beta treatment. Cytokine 8: 395-400
18. 18. Fujikawa Y, Shingu M, Torisu T, Masurni S (1995) Interleukin01 receptor antagonist production in cultured synovial cells from patients with rheumatoid arthritis and osteoarthritis. Ann Rheum Dis 54: 318-320
19. 19. Chomarat P, Vannier E, Dechanet J, Rissoani MC, Banchereau J, Dinarello CA, Mossec P (1995) Balance of IL-1 receptor antagonist / IL-1 Beta in rheumatoid synovium and its regulation by IL-4 and IL-10. J Immunol 154: 1432-1439
20. 20. Kristensen M, Deleuran B, Feldmann M, Breathnach SM, Brennan FM (1992) Distribution of interleukin 1 receptor antagonist protein (IRAP), interleukin 1 receptor, and interleukin 1 alpha in normal and psoriatic skin. Decreased expression of IRAP in psoriatic lesional epidermis. Br J Dermatol 127: 305-311
21. 21. Debets R, Hegmans JP, Croughs P, Troost RJ, Prins JB, Benner R, Prens EP. The IL-1 system in psoriatic skin: IL-1 antagonist sphere of influence in lesional psoriatic epidermis. J Immunol 158: 2955-2963